The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Improving treatment approaches for FLT3-mutated AML: insights into the Optimise-FLT3 trial
In this video, Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, UK, shares insights into the Optimise-FLT3 trial (ISRCTN34016918). This trial will randomize adults with FLT3-mutated acute myeloid leukemia (AML), building on the findings of AML19 (ISRCTN78449203), to optimize the combination of chemotherapy, gemtuzumab ozogamicin, and a FLT3 inhibitor. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
